Humacyte, Inc. — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2021-10-13

Reporting Person: Constantino Michael T. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-13	Stock Options (right to buy)	$10.03	A	13000	Acquired	2031-10-13	Common Stock (13000)	Direct

Footnotes

F1: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025.